§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US8163708B2 Active / In Force US ⏱️ 0.4 years remaining

Pharmaceutical composition comprising anti-mirna antisense oligonucleotide

Assignee: Roche Innovation Center Copenhagen AS
•
Filing: 2007-03-30
•
Granted: 2012-04-24
•
Expires: 2027-03-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.

Inventors

  • 👤 Joacim Elmén
  • 👤 Phil Kearney
  • 👤 Sakari Kauppinen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 22:43
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61P; A61P1/00; A61P1/16; A61P3/00; A61P3/06; A61P3/08; A61P3/10; A61P31/00; A61P31/12; A61P31/14; A61P35/00; A61P7/00; A61P9/00; A61P9/10; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/113; C12N2310/30; C12N2310/32; C12N2310/321; C12N2310/322; C12N2310/323; C12N2310/3231; C12N2310/35; C12N2310/351; C12N2310/3515

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 70 words
An oligonucleotide that is: (SEQ ID NO: 59) 5′- c s t s t s c s a s a s t s -3′ wherein: a lowercase letter identifies a DNA unit; an upper case bold letter identifies an LNA unit; m C identifies a 5-methylcytosine LNA; subscript s identifies a phosphorothioate internucleoside linkage, and the LNA units are beta-D-oxy, as identified by a o superscript after the LNA units.
Claim 2
Dependent Claim 70 words
An oligonucleotide that is: (SEQ ID NO: 59) 5′- c s t s t s c s a s a s t s -3′ wherein: a lowercase letter identifies a DNA unit; an upper case bold letter identifies an LNA unit; m C identifies a 5-methylcytosine LNA; subscript s identifies a phosphorothioate internucleoside linkage, and the LNA units are beta-D-oxy, as identified by a o superscript after the LNA units.
Claim 3
Dependent Claim 21 words
A composition comprising the oligonucleotide according to claim 1 , and a pharmaceutically acceptable diluent, carrier or adjuvant, or combinations thereof.

References Cited (Backward Citations)

US4962029A Cited
US4914210A Cited
US4920115A Cited
EP0699751A1 Cited
EP0662157B1 Cited
WO1994005813A1 Cited
US6433159B1 Cited
US6423489B1 Cited
US6284458B1 Cited
WO1995030746A1 Cited
US5919795A Cited
US6121283A Cited
US6030785A Cited
WO1999014226A2 Cited
WO2000056748A1 Cited
WO2000056746A2 Cited
WO2000066604A2 Cited
WO2001023613A1 Cited
EP1222309A1 Cited
WO2001025248A2 Cited
EP1099442A2 Cited
WO2002028875A2 Cited
US20030068320A1 Cited
WO2002081494A1 Cited
WO2002094250A2 Cited
WO2003006475A2 Cited
WO2003011887A2 Cited
WO2003029459A2 Cited
WO2003070750A2 Cited
WO2003095467A1 Cited
US20050069522A1 Cited
US20060040989A1 Cited
WO2004044181A2 Cited
WO2004046160A2 Cited
US20040204356A1 Cited
US20060035212A1 Cited
WO2004069991A2 Cited
WO2004076622A2 Cited
US7087229B2 Cited
US20050261218A1 Cited
WO2005013901A2 Cited
US20070049547A1 Cited
WO2005013905A2 Cited
WO2005023986A2 Cited
WO2005054494A2 Cited
WO2005058824A2 Cited
WO2005061710A1 Cited
WO2005078139A2 Cited
WO2005079397A2 Cited
US20050182005A1 Cited
WO2005098029A2 Cited
US20050227934A1 Cited
WO2005103298A2 Cited
WO2005107816A2 Cited
EP1747023B1 Cited
US7307067B2 Cited
WO2006093526A2 Cited
WO2006010423A2 Cited
WO2006112872A2 Cited
US20060035858A1 Cited
US20060058266A1 Cited
WO2006020768A2 Cited
WO2006020676A2 Cited
WO2006027776A1 Cited
WO2006036916A2 Cited
WO2006137941A2 Cited
WO2006053430A1 Cited
US20060185027A1 Cited
WO2006069584A2 Cited
WO2006113910A2 Cited
US20060265771A1 Cited
WO2006133022A2 Cited
WO2007021896A2 Cited
WO2007027775A2 Cited
EP1931782B1 Cited
WO2007027894A2 Cited
WO2007031091A2 Cited
WO2007031081A2 Cited
WO2007090073A2 Cited
WO2007112754A2 Cited
WO2007112753A2 Cited
US20100004320A1 Cited
WO2007146511A2 Cited
WO2007134181A2 Cited
WO2008025025A2 Cited
WO2008034123A2 Cited
WO2008034122A2 Cited
WO2008046911A2 Cited
WO2008057234A2 Cited
WO2008061537A2 Cited
WO2008074328A2 Cited
WO2008091703A2 Cited
WO2008113832A2 Cited
WO2008124384A2 Cited
WO2008150729A2 Cited
WO2008154401A2 Cited
US20090082297A1 Cited
WO2009020771A2 Cited
WO2009032083A1 Cited
WO2009043353A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2015-04-24 2015-10-24 2016-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2019-04-24 2019-10-24 2020-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2023-04-24 2023-10-24 2024-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag